Drugs / 211At-MABG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07661420 | Aug 2026 → Aug 2029 expected | bronchial endocrine tumor, digestive system neuroendocrine neoplasm, medullary thyroid gland carcinoma, paraganglioma +1 | University of Pennsylvania | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | \[211At\]MABG | “Astatine-211 \[211At\] is a short-lived α emitter conjugated onto meta-astatobenzylguanidine (\[211At\]MABG)” NCT07661420 ↗ |
| Modality | Other / unclassified | “Astatine-211 \[211At\] is a short-lived α emitter conjugated onto meta-astatobenzylguanidine (\[211At\]MABG)” NCT07661420 ↗ |
| Route | Intravenous | “administered by IV administration” NCT07661420 ↗ |